The goal of the Illuminating the Druggable Genome (IDG) Program is to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families. Currently, the pilot phase of the program is developing a website that integrates information about understudied proteins so that researchers everywhere can easily access it, catalyzing their own research and helping them find new proteins that may be of interest. In addition IDG is developing technologies to enable the study of understudied druggable proteins in a high throughput manner. The upcoming implementation phase of IDG aims to expand the informatics tools developed in the pilot phase, elucidate the function of understudied proteins from three key druggable protein families, and disseminate the IDG-generated resources to the greater scientific community.
The IDG Program was funded as a three-year pilot starting in 2014 with two goals. The first goal was to integrate information about understudied druggable proteins from disparate sources into a single informatics site. The second goal was to foster technology development to enable the determination of function and therapeutic potential of understudied druggable proteins at sufficient scale. The program is on track to be successful in accomplishing both of these goals.
The implementation phase of the IDG Program will capitalize on the information gathered and technologies developed in the first three years to elucidate the function of the unstudied proteins of the druggable genome.
Specifically, the implementation phase of the program is intended to:
- Expand the informatics tools developed in the pilot phase to include additional data and allow users to access a wide range of information on sets of proteins.
- Elucidate the function of understudied proteins from three key druggable protein families, non-olfactory G-protein coupled receptors (GPCRs), ion channels, and protein kinases.
- Disseminate the IDG-generated resources and data to the greater scientific community.
By focusing on understudied genes similar to those for which there are already many drugs, the IDG hopes to find potential targets for medications to treat or cure some of our most burdensome diseases – and then share what was learned so that all can build on this knowledge.
Learn More at the IDG Consortium Website
The goal of the Illuminating the Druggable Genome (IDG) program is to improve our understanding of the properties and functions of proteins that are currently unannotated within the four most commonly drug-targeted protein families: the G-protein coupled receptors, nuclear receptors, ion channels, and protein kinases. Learn more about the IDG Consortium by visiting the website
This page last reviewed on June 6, 2017